P047 Musculoskeletal symptoms as first clinical presentation of juvenile-onset systemic lupus erythematosus: Experience from a military internal medicine department

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_5) ◽  
Author(s):  
E Hannech ◽  
N Boussetta ◽  
N H Guediche ◽  
B Arfaoui ◽  
F Ajili ◽  
...  

Abstract Background Juvenile-onset systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder occurring before the age of sixteen. The clinical manifestations are variable and the management of the disease at this age may be different. The aim of our study was to investigate first clinical presentation of juvenile-onset SLE. Methods We conducted a retrospective study in a military internal medicine department. We accessed medical records of 103 patients with SLE diagnosed according to the revised 1997 American College of Rheumatology (ACR) criteria or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. Only patients with an age of lupus-onset < the age of sixteen were included. Clinical data were collected and analyzed. The statistical analysis was performed using SPSS 23.0 software. Result There were eight juvenile-onsets SLE: two males and six females. The median age at the diagnosis was 13.7 + 1.9 years-old (11–16). First clinical presentations are shown in table 1. Arthritis and hematological involvement tended to be associated (p = 0.07). Hypocomplementemia and positive anti-DNA antibodies were detected in 50% of cases. All patients received Hydroxychloroquine and most of them combined corticosteroids (7cases). Conclusion Our study showed that musculoskeletal manifestations especially arthritis were frequent at the diagnosis of juvenile-onset SLE. According to the aggressive pharmacological treatment, a multidisciplinary approach should be required

2019 ◽  
Vol 209 ◽  
pp. 108274 ◽  
Author(s):  
Eve Mary Dorothy Smith ◽  
Hanna Lythgoe ◽  
Angela Midgley ◽  
Michael William Beresford ◽  
Christian Michael Hedrich

2015 ◽  
Vol 27 (5) ◽  
pp. 1839-1848 ◽  
Author(s):  
J. A. Paupitz ◽  
G. L. Lima ◽  
J. C. Alvarenga ◽  
R. M. Oliveira ◽  
E. Bonfa ◽  
...  

2001 ◽  
Vol 21 (3) ◽  
pp. 103-105 ◽  
Author(s):  
Huang J.-L. ◽  
Shaw C.-K. ◽  
Lee A. ◽  
Lee T.-D. ◽  
Wu Chou ◽  
...  

2015 ◽  
Vol 67 (11) ◽  
pp. 1609-1614 ◽  
Author(s):  
Elisabeth C. Fernandes ◽  
Clovis A. Silva ◽  
Alfésio L. F. Braga ◽  
Adriana M. E. Sallum ◽  
Lúcia M. A. Campos ◽  
...  

2017 ◽  
Vol 18 (6) ◽  
pp. 755-762 ◽  
Author(s):  
Pongsawat Rodsaward ◽  
Titipong Prueksrisakul ◽  
Tawatchai Deekajorndech ◽  
Steven W. Edwards ◽  
Michael W. Beresford ◽  
...  

Author(s):  
Louise Watson ◽  
Michael W. Beresford

Paediatric or juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune condition, differing from the adult form in terms of severity, organ manifestations, and a less striking female predominance. The diagnosis relies on the adult-derived American College of Rheumatology SLE classification criteria. Genetic, autoantibody, and host immune responses, characteristic of this disease, result in a clinically heterogeneous phenotype. A proportion of paediatric SLE patients will have evidence of a genetic deficiency known to be associated with SLE, such as C1q deficiency, and screening for these is required. A challenging diagnosis to make in the younger age group, the management of JSLE compared to adult-onset SLE requires special consideration towards the significant long-term consequences of the disease and treatment toxicity, combined with an onset during a fundamental time with regards to growth and development. A comprehensive, multidisciplinary team approach to the management of JSLE is essential. With a more severe phenotype and limited comorbidities, patients with JSLE represent an invaluable opportunity for investigating the pathogenesis. To date, clinical trials informing interventions in JSLE are very limited and treatment choices rely on the outcome of adult trials. Patient and family involvement in research to improve outcomes and understanding is essential. New treatments, including biological therapies, are becoming available for clinical use and new treatment combinations have been used to induce and maintain clinical remission.


Sign in / Sign up

Export Citation Format

Share Document